These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 33325391)
1. Brain Bio-Energetic State Does Not Correlate to Muscle Mitochondrial Function in Huntington's Disease. van Diemen MPJ; Hart EP; Hameeteman PW; Coppen EM; Winder JY; den Heijer J; Moerland M; Kan H; van der Grond J; Webb A; Roos RAC; Groeneveld GJ J Huntingtons Dis; 2020; 9(4):335-344. PubMed ID: 33325391 [TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study. van Diemen MPJ; Hart EP; Abbruscato A; Mead L; van Beelen I; Bergheanu SC; Hameeteman PW; Coppen E; Winder JY; Moerland M; Kan H; van der Grond J; Webb A; Roos RAC; Groeneveld GJ Br J Clin Pharmacol; 2021 May; 87(5):2290-2302. PubMed ID: 33197078 [TBL] [Abstract][Full Text] [Related]
3. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease. Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751 [TBL] [Abstract][Full Text] [Related]
4. Huntington's Disease and Mitochondria. Jodeiri Farshbaf M; Ghaedi K Neurotox Res; 2017 Oct; 32(3):518-529. PubMed ID: 28639241 [TBL] [Abstract][Full Text] [Related]
5. Clinical correlates of mitochondrial function in Huntington's disease muscle. Turner C; Cooper JM; Schapira AH Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337 [TBL] [Abstract][Full Text] [Related]
6. Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease. Rodinova M; Krizova J; Stufkova H; Bohuslavova B; Askeland G; Dosoudilova Z; Juhas S; Juhasova J; Ellederova Z; Zeman J; Eide L; Motlik J; Hansikova H Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31278192 [TBL] [Abstract][Full Text] [Related]
7. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Lodi R; Schapira AH; Manners D; Styles P; Wood NW; Taylor DJ; Warner TT Ann Neurol; 2000 Jul; 48(1):72-6. PubMed ID: 10894218 [TBL] [Abstract][Full Text] [Related]
8. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients. Askeland G; Dosoudilova Z; Rodinova M; Klempir J; Liskova I; Kuśnierczyk A; Bjørås M; Nesse G; Klungland A; Hansikova H; Eide L Sci Rep; 2018 Jun; 8(1):9817. PubMed ID: 29959348 [TBL] [Abstract][Full Text] [Related]
10. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331 [TBL] [Abstract][Full Text] [Related]
11. Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Schapira A; Lodi R Methods Mol Biol; 2004; 277():293-307. PubMed ID: 15201464 [TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic characteristics in patients with Huntington's disease from China. Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361 [TBL] [Abstract][Full Text] [Related]
16. Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients. Chang KH; Wu YR; Chen CM Orphanet J Rare Dis; 2017 Dec; 12(1):185. PubMed ID: 29258536 [TBL] [Abstract][Full Text] [Related]
17. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease. Tobore TO J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621 [TBL] [Abstract][Full Text] [Related]
18. Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. Agrawal S; Fox J; Thyagarajan B; Fox JH Free Radic Biol Med; 2018 May; 120():317-329. PubMed ID: 29625173 [TBL] [Abstract][Full Text] [Related]
19. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861 [TBL] [Abstract][Full Text] [Related]
20. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting. Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]